Evaluation of a Standardized Treatment Regimen for Antibody Mediated Rejection Following Lung Transplantation
Clinical Transplantation · 2026-11 · 40 (11)
DOI: 10.1111/ctr.70737 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Transplantation, online erschienen am 01.11.2026. Verfasst von Richard W Lincoln und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Barnes-Jewish Hospital, Saint Louis, Missouri, USA. Hauptthemen laut MEDLINE: Graft Rejection, Lung Transplantation, Immunosuppressive Agents, Isoantibodies. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
Background
The treatment of antibody mediated rejection (AMR) in lung transplant recipients (LTRs) requires a multi‐modal approach targeting various pathways in the immune system. There currently is no consensus on what the standard therapy for AMR in LTRs should be. This study evaluates the efficacy of a standardized treatment protocol versus a non‐standardized approach.
Methods
This retrospective, single‐center study evaluated LTRs treated for AMR with either a standard treatment approach consisting of methylprednisolone, carfilzomib, anti‐thymocyte globulin, tocilizumab, and intravenous immunoglobulins or a non‐standardized approach. The primary outcome was the incidence of graft loss within 1 year of AMR treatment. Secondary endpoints included the incidence of infections and chronic lung allograft dysfunction (CLAD) within 1 year from AMR treatment.
Results
Thirteen patients were included in the standard and 38 patients in the non‐standard cohorts. Median time from transplant to AMR was 606 (160–935) days in the standard cohort and 314 (92–541) days in the non‐standard cohort ( p = 0.125). Graft loss within 1 year from AMR was 30.8% and 39.5% for the standard and non‐standard cohorts, respectively ( p = 0.416). The incidence of CLAD (69.2% vs 68% [ p = 0.619]) and infections (53.8% vs 65.8% [ p = 0.504]) were similar in the standard and non‐standard cohorts.
Conclusion
In this retrospective study, there was numerically better 1 year graft survival in the standard cohort vs the non‐standard cohort but no difference in incidence of CLAD and infections post AMR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Barnes-Jewish Hospital, Saint Louis, Missouri, USA.
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA.
ORCID-Profile: Richard W Lincoln, Keith A Fester, Sahil Sanghani, Chad A Witt, Spenser January
Zitieren
APA
Lincoln, R. W., Hipkiss, E., Fester, K. A., Sanghani, S., Witt, C. A., & January, S. (2026). Evaluation of a Standardized Treatment Regimen for Antibody Mediated Rejection Following Lung Transplantation. Clinical Transplantation, 40(11). https://doi.org/10.1111/ctr.70737
Vancouver
Lincoln RW, Hipkiss E, Fester KA, Sanghani S, Witt CA, January S. Evaluation of a Standardized Treatment Regimen for Antibody Mediated Rejection Following Lung Transplantation. Clinical Transplantation. 2026;40(11). doi:10.1111/ctr.70737
BibTeX
@article{Lincoln2026,
author = {Lincoln, Richard W and Hipkiss, Elizabeth and Fester, Keith A and Sanghani, Sahil and Witt, Chad A and January, Spenser},
title = {Evaluation of a Standardized Treatment Regimen for Antibody Mediated Rejection Following Lung Transplantation},
journal = {Clinical Transplantation},
year = {2026},
volume = {40},
number = {11},
doi = {10.1111/ctr.70737}
}
EUVIMED